

D2 4. (Amended) The method of claim 1 wherein the administered substance is an anti-CD28 agonist antibody.

5. (Amended) The method of claim 1 wherein the subject is a human subject.

DB 9. (Twice Amended) The method of claim 5 wherein the human subject is aged from about 6 months to about 2 or 3 years.

REMARKS

Claims 1-31 are pending. Claims 7 and 10-31 were subject to a restriction requirement and were previously canceled. Claims 1-6, 8, and 9 are presently under examination and stand rejected. In the instant amendment, claims 2, 3, and 8 are canceled, and claims 1, 4, 5, and 9 are amended. Reconsideration of the claims is respectfully requested. The paragraph numbering below follows that of the Office Action (Paper Number 21).

All amendments are for purposes of expediting prosecution and should not be construed as an acquiescence in any ground of rejection. Claim 1 has been amended to recite a method for preventing the development of autoimmune diabetes comprising administering certain CD28 agonists to expedite prosecution without conceding that the Examiner's rejection is warranted on this basis. Claims 4, 5, and 9 have been amended to adjust their dependencies.

Rejections under 35 U.S.C. 112

¶5 Claims 1-6 and 8-9 were rejected under 35 U.S.C. §112, first paragraph, on the grounds that, while the specification enables a method of preventing autoimmune diabetes with an agonist antibody to CD28, it allegedly does not provide enablement for a method of preventing the development of other autoimmune diseases (claims 1-6), preventing the development of diabetes in individuals not susceptible to the